Salalah: In a significant advancement towards fortifying the healthcare sector of Oman, the Dhofar Pharmaceutical Industries Factory was officially inaugurated on Wednesday at the Raysut Industrial City in Salalah.
With an investment surpassing OMR15 million, this state-of-the-art facility is designed to enhance the nation's pharmaceutical security and diminish its reliance on foreign imports by producing intravenous and kidney dialysis solutions domestically.
The inauguration ceremony was conducted by Qais bin Mohammed Al Yousef, Minister of Commerce, Industry, and Investment Promotion, in the presence of Dr. Hilal bin Ali Al Sabti, Minister of Health, and other distinguished guests.
Located over a vast 22,000 square meters, the facility is equipped with cutting-edge German technologies and meets the highest international standards. This project is poised to significantly contribute to fulfilling the local and regional demand for pharmaceutical solutions, thereby strengthening Oman's health security and its ambition to reduce dependence on imports.
"This factory represents the culmination of the Health Sector Investment Lab, launched by the Ministry of Health in 2022, in collaboration with Nazdar, and is in alignment with Oman Vision 2040," stated Al Yousef.
He underscored the importance of this facility as a pivotal element in the industrial expansion within Dhofar Governorate, highlighting its contribution to Oman's strategic objectives in both health and industry.
Capable of producing 15 million units of intravenous solutions and 2.3 million units of kidney dialysis solutions annually, the factory is well-positioned to meet the projected demand of 5 million units annually within Oman's healthcare sector.
Sheikh Salem bin Ali Amer Jaid Al Mahri, Chairman of Dhofar Pharmaceutical Industries, emphasized the company's commitment to leveraging national talent and expertise to ensure the production of high-quality pharmaceuticals.
Dr. Mohammed bin Hamdan Al-Rubaie, Director General of the Drug Safety Centre at the Ministry of Health, noted that the facility adheres to the standards set by both the US FDA and the European Medicines Agency, further establishing its significance as a strategic initiative that enhances Oman's self-reliance in essential medical supplies.
This facility is not only intended to stabilize local prices but also to reduce Oman's vulnerability to fluctuations in international markets, thereby reinforcing Oman's position in the global pharmaceutical industry and fostering research and innovation within the sector.
The inauguration of this factory represents a significant milestone in the development of a more resilient and sustainable healthcare system, ensuring that Oman is better prepared to respond to emergencies and enhance patient care.
